...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.
【24h】

A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.

机译：挽救伊立替康单药治疗晚期胆道癌的初步研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To evaluate the treatment outcomes of irinotecan monotherapy for patients with advanced biliary tract cancer refractory to gemcitabine, cisplatin, and oral fluoropyrimidine.Irinotecan (100 mg/m(2)) was administered intravenously on days 1, 8, and 15, repeated every four weeks.Thirteen patients were enrolled. The dose intensity was only 55.0%. The response rate and disease control rate were 1/13 (7.7%) and 3/13 (23.1%), respectively. The median overall survival and time-to-progression were 6.7 months (95% confidence interval=3.0-10.4 months) and 1.8 months (95% confidence interval=1.6-3.9 months), respectively. Grade 3/4 adverse events included leukopenia (7/13), neutropenia (8/13), anemia (6/13), nausea (1/13), vomiting (1/13), anorexia (2/13), diarrhea (1/13), and constipation (1/13).Irinotecan monotherapy had a modest antitumor effect even for patients who were refractory to gemcitabine, cisplatin, and oral fluoropyrimidine. However, this regimen was not fully tolerated as third-line or fourth-line therapy. Therefore, further evaluation of a modified irinotecan regimen is necessary.
机译：为了评估伊立替康单一疗法对难治性吉西他滨，顺铂和口服氟嘧啶的晚期胆道癌患者的治疗效果。伊立替康（100 mg / m（2））在第1、8和15天静脉注射周。招募了十三名患者。剂量强度仅为55.0％。缓解率和疾病控制率分别为1/13（7.7％）和3/13（23.1％）。中位总生存期和进展时间分别为6.7个月（95％置信区间= 3.0-10.4个月）和1.8个月（95％置信区间= 1.6-3.9个月）。 3/4级不良事件包括白细胞减少症（7/13），中性粒细胞减少症（8/13），贫血（6/13），恶心（1/13），呕吐（1/13），厌食症（2/13），腹泻（1/13）和便秘（1/13）。伊立替康单药治疗即使对吉西他滨，顺铂和口服氟嘧啶难治的患者也具有适度的抗肿瘤作用。但是，这种方案不能完全耐受作为三线或四线治疗。因此，有必要进一步评估改良的伊立替康治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号